ARTICLEPharmacotherapy of First-Episode SchizophreniaLiffick, Emily MD; Breier, Alan MDEditor(s): Janicak, Philip G. MD, Editor Author Information Dr. Liffick is Assistant Professor of Clinical Psychiatry, Department of Psychiatry, Indiana University School of Medicine, Midtown Community Mental Health Center, 1001 W. 10th Street, BU-44, Indianapolis, IN 46202, E-mail: [email protected]; and Dr. Breier is Professor of Psychiatry, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN. Unless otherwise noted below, each faculty and staff's spouse/ life partner (if any) has nothing to disclose. Dr. Brier has disclosed that he is an employee of Eli Lilly. Dr. Liffick and all editors and staff in a position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations pertaining to this educational activity. The authors have disclosed that the use of N-acetyl cysteine for treatment of first-episode schizophrenia as discussed in this article has not been approved by the U.S. Food and Drug Administration. Lippincott CME Institute, Inc., has identified and resolved all faculty and staff conflicts of interest regarding this educational activity. Psychopharm Review: June 2010 - Volume 45 - Issue 6 - p 41-48 doi: 10.1097/01.IDT.0000372139.52401.97 Buy CME Test Metrics © 2010 Lippincott Williams & Wilkins, Inc.